Affimed (AFMD) Revenue & Revenue Breakdown
Affimed Revenue Highlights
Latest Revenue (Y)
$8.28M
Latest Revenue (Q)
$155.00K
Main Segment (Y)
Collaboration
Main Geography (Y)
USA
Affimed Revenue by Period
Affimed Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $8.28M | -79.99% |
2022-12-31 | $41.35M | 2.45% |
2021-12-31 | $40.37M | 42.33% |
2020-12-31 | $28.36M | 32.58% |
2019-12-31 | $21.39M | -9.88% |
2018-12-31 | $23.73M | 1080.85% |
2017-12-31 | $2.01M | -68.17% |
2016-12-31 | $6.31M | -16.50% |
2015-12-31 | $7.56M | 123.60% |
2014-12-31 | $3.38M | -33.52% |
2013-12-31 | $5.09M | 333.67% |
2012-12-31 | $1.17M | - |
Affimed Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $155.00K | -62.47% |
2023-12-31 | $413.00K | -78.95% |
2023-09-30 | $1.96M | 41.15% |
2023-06-30 | $1.39M | -69.18% |
2023-03-31 | $4.51M | -59.58% |
2022-12-31 | $11.16M | -25.05% |
2022-09-30 | $14.89M | 103.92% |
2022-06-30 | $7.30M | -8.81% |
2022-03-31 | $8.01M | -22.56% |
2021-12-31 | $10.34M | 19.35% |
2021-09-30 | $8.66M | -10.77% |
2021-06-30 | $9.71M | -16.74% |
2021-03-31 | $11.66M | 19.63% |
2020-12-31 | $9.75M | -7.58% |
2020-09-30 | $10.54M | 259.41% |
2020-06-30 | $2.93M | -42.86% |
2020-03-31 | $5.13M | 30.76% |
2019-12-31 | $3.93M | 86.73% |
2019-09-30 | $2.10M | -47.53% |
2019-06-30 | $4.01M | -64.70% |
2019-03-31 | $11.35M | -50.09% |
2018-12-31 | $22.75M | 7333.66% |
2018-09-30 | $306.00K | 104.00% |
2018-06-30 | $150.00K | -71.80% |
2018-03-31 | $532.00K | -16.35% |
2017-12-31 | $636.00K | 36.19% |
2017-09-30 | $467.00K | -8.07% |
2017-06-30 | $508.00K | 27.32% |
2017-03-31 | $399.00K | -70.90% |
2016-12-31 | $1.37M | 46.16% |
2016-09-30 | $938.00K | -54.66% |
2016-06-30 | $2.07M | 6.87% |
2016-03-31 | $1.94M | 16.70% |
2015-12-31 | $1.66M | 43.64% |
2015-09-30 | $1.16M | -47.74% |
2015-06-30 | $2.21M | -12.92% |
2015-03-31 | $2.54M | 3033.33% |
2014-12-31 | $81.00K | -95.72% |
2014-09-30 | $1.89M | 175.40% |
2014-06-30 | $687.00K | -4.85% |
2014-03-31 | $722.00K | -84.39% |
2013-12-31 | $4.63M | 2321.47% |
2013-09-30 | $191.00K | -4.98% |
2013-06-30 | $201.00K | 187.14% |
2013-03-31 | $70.00K | - |
Affimed Revenue Breakdown
Affimed Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
Collaboration | $7.76M | $41.20M | $39.30M | - | - |
Service | $510.00K | $155.00K | $1.06M | - | - |
Services | - | - | - | $605.00K | $1.71M |
Collaboration Service | - | - | - | $27.75M | $19.68M |
Quarterly Revenue by Product
Product/Service | Dec 23 | Jun 23 | Jun 22 | Jun 21 | Jun 20 | Jun 19 |
---|---|---|---|---|---|---|
Collaboration | $6.55M | $1.22M | $7.28M | - | - | - |
Service | $335.00K | $175.00K | $17.00K | - | - | - |
Services | - | - | - | $222.00K | $141.00K | $325.00K |
Collaboration Service | - | - | - | $9.48M | $2.79M | $3.68M |
Affimed Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
USA | $8.27M | $41.20M | $39.62M | - | - |
Germany | $5.00K | $152.00K | $742.00K | - | - |
Europe | - | - | - | $2.00K | $1.65M |
U | - | - | - | $28.16M | $19.75M |
D | - | - | - | $194.00K | - |
Quarterly Revenue by Country
Country | Dec 23 | Jun 23 | Jun 22 | Jun 21 | Jun 20 | Jun 19 |
---|---|---|---|---|---|---|
USA | $6.88M | $1.39M | $7.29M | - | - | - |
Germany | - | - | $14.00K | - | - | - |
U | - | - | - | $9.48M | $2.93M | $3.68M |
D | - | - | - | $222.00K | - | - |
Europe | - | - | - | - | - | $325.00K |
Affimed Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AGEN | Agenus | $156.31M | $23.51M |
ADCT | ADC Therapeutics SA | $69.56M | $17.03M |
ADAP | Adaptimmune Therapeutics | $60.28M | $128.37M |
PIRS | Pieris Pharmaceuticals | $42.81M | - |
MREO | Mereo BioPharma Group | $10.00M | - |
AFMD | Affimed | $8.28M | $155.00K |
CRVS | Corvus Pharmaceuticals | - | - |
APTO | Aptose Biosciences | - | - |
XFOR | X4 Pharmaceuticals | - | $563.00K |
PDSB | PDS Bio | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
INZY | Inozyme Pharma | - | - |
LPTX | Leap Therapeutics | - | - |
ELEV | Elevation Oncology | - | - |
TERN | Terns Pharmaceuticals | - | - |
HEPA | Hepion Pharmaceuticals | - | - |
EFTR | eFFECTOR Therapeutics | - | - |
AFMD Revenue FAQ
What is Affimed’s yearly revenue?
Affimed's yearly revenue for 2023 was $8.28M, representing a decrease of -79.99% compared to 2022. The company's yearly revenue for 2022 was $41.35M, representing an increase of 2.45% compared to 2021. AFMD's yearly revenue for 2021 was $40.37M, representing an increase of 42.33% compared to 2020.
What is Affimed’s quarterly revenue?
Affimed's quarterly revenue for Q1 2024 was $155K, a -62.47% decrease from the previous quarter (Q4 2023), and a -96.56% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $413K, a -78.95% decrease from the previous quarter (Q3 2023), and a -96.30% decrease year-over-year (Q4 2022). AFMD's quarterly revenue for Q3 2023 was $1.96M, a 41.15% increase from the previous quarter (Q2 2023), and a -86.82% decrease year-over-year (Q3 2022).
What is Affimed’s revenue growth rate?
Affimed's revenue growth rate for the last 3 years (2021-2023) was -79.50%, and for the last 5 years (2019-2023) was -61.32%.
What are Affimed’s revenue streams?
Affimed's revenue streams in c 23 are Collaboration, and Service. Collaboration generated $7.76M in revenue, accounting 93.84% of the company's total revenue, down -81.15% year-over-year. Service generated $510K in revenue, accounting 6.16% of the company's total revenue, up 229.03% year-over-year.
What is Affimed’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Affimed was Collaboration. This segment made a revenue of $7.76M, representing 93.84% of the company's total revenue.